PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 701–800 of 1,009
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Mpekris, F., Panagi, M., Charalambous, A., Voutouri, C., & Stylianopoulos, T. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101626 · Cited by 78
“57 Specifically, HIF-1 a was found to upregulate PD-L1 on breast and prostate cancer cells.”
Zou, M., Guo, K.-M., Lv, G., Huang, W., Li, J., Wang, X., Jiang, Y., & She, X. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2080-1 · Cited by 53
“It will be interesting to postulate that PD-L1 upregulation in chordoma may be induced by the hypoxia conditions [52, 53].”
BackgroundTung, J.-N., Lin, P.-L., Wang, Y.-C., Wu, D., Chen, C.-Y., & Lee, H. (2017) · Oncotarget · doi:10.18632/oncotarget.23161 · Cited by 53
“PD-L1 is a novel direct target of HIF-1α and its blockade under hypoxia enhances MDSC-mediated T cell activation [27].”
BackgroundTGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
Alvarez, M. A., Freitas, J. P., Hussain, S. M., & Glazer, E. S. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-018-00195-5 · Cited by 56
Zhu, Z., Pang, Y., Jin, G., Zhang, H., Wang, W., Liu, J.-W., Tuo, G., Wu, P., Yang, Y., Wang, Z.-Q., et al. (2021) · Aging · doi:10.18632/aging.203062 · Cited by 51
“The novel lncRNA EMS was identified as a direct c-Myc transcriptional target that functions as an oncogenic gene by increasing E2F1 expression and promoting G1/S cell cycle progression in lung cancer cells [22].”
BackgroundCell Component and Function of Tumor Microenvironment in Thyroid Cancer
Shin, E., & Koo, J. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012578 · Cited by 60
“Possible biomarkers for cancer immunotherapy in general are PD-L1, tumor mutation burden (TMB), microsatellite instability (MSI), specific gene mutation, immunogenic neo-antigen, and gut microbiome [151], and possible application of these biomarkers for immunotherapy in thyroid cancers should be explored in further st…”
BackgroundInfluentialRecent progress in immune evasion mechanisms of triple-negative breast cancer
Yang, Y., & Wang, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07370-w · Cited by 63
Wang, X., Luo, X., Xiao, R., Liu, X., Zhou, F., Jiang, D., Bai, J., Cui, M., You, L., & Yupei, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02334-4 · Cited by 65
Ortiz, J. A., Maroun‐Eid, C., Martín‐Quirós, A., Toledano, V., Cubillos‐Zapata, C., Gómez‐Campelo, P., Varela-Serrano, A., Casas-Martín, J., Llanos-González, E., Álvarez, E., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix279 · Cited by 54
Choi, J. W., Kim, Y. J., Yun, K. A., Won, C. H., Lee, M. W., Choi, J. H., Chang, S. E., & Lee, W. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-71216-2 · Cited by 52
Zhang, Y., Ware, M. B., Zaidi, M. Y., Ruggieri, A. N., Olson, B. M., Komar, H. M., Farren, M. R., Nagaraju, G. P., Zhang, C., Chen, Z., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0911 · Cited by 57
Khouzam, R. A., Rao, R. S. P., Venkatesh, G. H., Zeinelabdin, N. A., Buart, S., Meylan, M., Nimmakayalu, M. A., Terry, S., & Chouaïb, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680435 · Cited by 55
Lee, H. J., Min, H.-Y., Yong, Y.-S., Ann, J., Nguyen, C.-T., La, M. T., Hyun, S. Y., Le, H. T., Kim, H., Kwon, H.-J., et al. (2021) · Theranostics · doi:10.7150/thno.63788 · Cited by 52
“Of note, some transcription factors involved in the regulation of PD-L1 expression such as hypoxia inducible factor-1 alpha (HIF-1α) and STAT3 [52, 53] are Hsp90 client proteins [46].”
BackgroundGe, Y., Yoon, S.-H., Jang, H., Jeong, J.-H., & Lee, Y.-M. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153318 · Cited by 49
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 58
“PD-L1 as well as CTLA-4 [153,154] have been shown to be upregulated under hypoxia, decreasing ICI efficacy.”
BackgroundSato, Y., Shimizu, K., Shinga, J., Hidaka, M., Kawano, F., Kakimi, K., Yamasaki, S., Asakura, M., & Fujii, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.995541 · Cited by 51
“It was shown that IL-10 is also produced by MDSCs.(31-33) Therefore, we also focused on the importance of IL-10 production by MDSC subsets in this study.”
BackgroundCasacuberta‐Serra, S., Parés, M., Golbano, A., Coves, E., Espejo, C., & Barquinero, J. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.4 · Cited by 52
Revision of the concept of anti‐angiogenesis and its applications in tumor treatment
Yang, W., Xu, J., Mu, J., & Xie, J. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.01.002 · Cited by 53
“Hypoxia can upregulate the expression of programmed death-ligand 1 (PD-L1), an immune checkpoint protein, and increase tumor cells' resistance to cytotoxic T lymphocytes-mediated lysis.(31,32) As a result, tumor vessel normalization by VEGF and its receptors can subsequently activate antitumor immunity, thus creating…”
BackgroundKoh, Y. W., Han, J.-H., Yoon, D. H., Suh, C., & Huh, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3115-6 · Cited by 50
“HIF-1α also significantly increases the expression of PD-L1 in macrophages, dendritic cells, and tumor cells [33].”
BackgroundResultGiatromanolaki, A. N., Koukourakis, I. M., Balaska, K., Mitrakas, A. G., Harris, A. L., & Koukourakis, M. I. (2019) · Medical Oncology · doi:10.1007/s12032-019-1299-4 · Cited by 49
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 55
“In addition, using a ccRCC model, HIF-1α and HIF-2α were found to upregulate PD-L1 expression on MDSCs, TAMs, and DCs through directly binding to hypoxia response element (HRE) (Figure 3A) (134, 135).”
MethodZhao, A., Xu, H., Kang, X., Zhao, A., & Lu, L. (2015) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2015.11.001 · Cited by 53
Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword
Wang, J., Liu, N., Jiang, H., Qian, L., & Xing, D. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.784612 · Cited by 50
“…stabilization of multiple transcription factors such as NFκB and HIF-1α, while NFκB initiates PD-L1 expression by binding to the PD-L1 promoter (Guo et al., 2019), and HIF-1α directly binds to a transcriptionally active hypoxia-response element in the PD-L1 proximal promoter (Noman et al., 2014).”
BackgroundNeutrophil metabolism in the cancer context
Bodac, A., & Meylan, E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101583 · Cited by 52
“HIF-1α can also promote the expression of PD-L1 on MDSCs, inhibiting T cell activation [57].”
BackgroundUltrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy
Voutouri, C., Mpekris, F., Panagi, M., Krolak, C., Michael, C., Martin, J. D., Averkiou, M. A., & Stylianopoulos, T. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.007 · Cited by 51
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer
Fang, B., Lu, Y., Li, X., Yu, W., Ye, D., Wei, G., & Zhu, Y. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00825-z · Cited by 61
“…known to participate in constituting suppressive TME through high expression of inhibitory immune checkpoint molecules (e.g., PD-L1, VISTA, Gal-9) [52 – 54] or massive secretion of arginase-1, reactive oxygen species (ROS) and reactive nitrogen species (RNS) to negatively modulate T cells…”
Wang, R., Zhuang, J., Zhang, Q., Wu, W., Yu, X., Zhang, H., & Xie, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00689-6 · Cited by 60
The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation
Trivanović, D., Krstić, J., Djordjević, I. O., Mojsilović, S., Santibanez, J. F., Bugarski, D., & Jauković, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/7314016 · Cited by 46
“However, it has been demonstrated that HIF-1 controls generation of tolerogenic immune cells in TME, such as Treg [34], MDSCs [35], and tumor-associated macrophages (TAMs) [36].”
BackgroundTherapeutic prospects of targeting myeloid‐derived suppressor cells and immune checkpoints in cancer
Toor, S. M., & Elkord, E. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12054 · Cited by 51
“Moreover, there is no consensus among the scientific community on highly specific markers to identify human MDSC.”
BackgroundInfluentialBridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
“2); hypoxic induction of PD-L1 has also been demonstrated in lung carcinomas and clear cell renal cell carcinomas (RCCs) (91, 111, 134).”
BackgroundA rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
Guisier, F., Cousse, S., Jeanvoine, M., Thiberville, L., & Salaün, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52913-z · Cited by 51
Sellam, L.-S., Zappasodi, R., Chettibi, F., Djennaoui, D., mesbah, N. Y. A., Amir, Z.-C., Touil–Boukoffa, C., Ouahioune, W., Merghoub, T., & Bourouba, M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108479 · Cited by 52
Metabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment
de Goede, K. E., Driessen, A. J. M., & den Bossche, J. V. (2020) · Biology · doi:10.3390/biology9110380 · Cited by 56
“TAMs exert immunosuppressive functions by several mechanisms: expression of programmed death ligand 1 (PD-L1), thereby limiting T cell responses [10]; secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor β (TGFβ) [11]; recruitment of regulatory T cells (Tregs) via chem…”
BackgroundYang, A., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., Piao, L. X., Jin, H. L., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113598 · Cited by 50
Cartwright, A. N. R., Suo, S., Badrinath, S., Kumar, S., Melms, J. C., Luoma, A., Bagati, A., Saadatpour, A., Izar, B., Yuan, G., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0085 · Cited by 56
Zhou, J., Wang, W., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01873-2 · Cited by 53
“With the help of HIF-1α, which binds the HRE in the promoter of the PD-L1 gene, the expression of PD-L1 is significantly increased in many types of tumor cells, including melanoma, lung cancer, breast cancer, and prostate cancer cells [100, 101].”
BackgroundHuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
Liu, Y., Li, X., Zhang, H., Zhang, M., & Wei, Y. (2021) · Oncogene · doi:10.1038/s41388-021-01689-6 · Cited by 51
Manganese oxide nanomaterials boost cancer immunotherapy
Ding, B., Yue, J., Zheng, P., Ma, P., & Lin, J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01001h · Cited by 49
Zheng, Y., Li, H., Chen, Z., Li, Y., Zhou, B., Hu, R., Chen, S., Xiao, H., Ma, Y., Xie, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103785 · Cited by 55
“Transcription factors such as STAT1, STAT3, NF-kB, and HIF-1a are known to activate PD-L1 expression in response to inflammatory and metabolic cues from the TME (Noman et al., 2014; Lee et al., 2006).”
BackgroundInfluentialGui, C., Wei, J., Chen, Y., Fu, L., Tang, Y., Cao, J., Chen, W., & Luo, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab173 · Cited by 46
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 52
“Moreover, HIFs also upregulate the expression of the inhibitory checkpoints [PD-L1 (56, 57), cluster of differentiation 47 (CD47) (58) and human leukocyte antigen G (HLA-G) (59)] to assist immune compromise.”
BackgroundHatziioannou, A., Alissafi, T., & Verginis, P. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-493r · Cited by 47
“demonstrated that PD-L1 was a novel, direct target of HIF-1a, and its blockade during cancer development enhanced MDSC-mediated T cell activation [181].”
BackgroundCancer, obesity and immunometabolism – Connecting the dots
Dyck, L., & Lynch, L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.019 · Cited by 51
Chae, Y. K., Choi, W. M., Bae, W. H., Anker, J. F., Davis, A. A., Agte, S., Iams, W. T., Cruz, M. R. D. S., Matsangou, M., & Giles, F. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-19454-3 · Cited by 50
Namkoong, H., Ishii, M., Fujii, H., Yagi, K., Asami, T., Asakura, T., Suzuki, S., Hegab, A. E., Kamata, H., Tasaka, S., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006955 · Cited by 48
Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo
Solito, S., Pinton, L., Sanctis, F. D., Ugel, S., Bronte, V., Mandruzzato, S., & Marigo, I. (2018) · Current Protocols in Immunology · doi:10.1002/cpim.61 · Cited by 53
Self-citationDifferential effect of intermittent hypoxia and sleep fragmentation on PD-1/PD-L1 upregulation
Cubillos‐Zapata, C., Almendros, I., Díaz‐García, E., Toledano, V., Casitas, R., Galera, R., López‐Collazo, E., Farré, R., Gozal, D., & Rio, F. G. (2019) · SLEEP · doi:10.1093/sleep/zsz285 · Cited by 53
“Furthermore, IH also compromises the pathway of the programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) [16], which plays a critical role in the development and progression of cancer and is currently one of the main targets for cancer immunotherapy [17, 18].”
BackgroundModern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
“The induction of hypoxia-inducible factor-1α (HIF-1α) through transforming growth factor-β (TGF-β) and hypoxic conditions leads to the upregulation of the ectoenzymes CD39 and CD73, producing immunosuppressive adenosine in the extracellular space [40,41].”
BackgroundManipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
Pellegrino, M., Bufalo, F. D., Angelis, B. D., Quintarelli, C., Caruana, I., & de Billy, E. (2020) · Cells · doi:10.3390/cells10010014 · Cited by 48
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma
Hu, C., Wang, K., Damon, C., Fu, Y., Ma, T., Kratz, L. E., Lal, B., Ying, M., Xia, S., Cahill, D. P., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab292 · Cited by 50
RETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47
“Another drawback of hypoxia is the upregulation of an immune checkpoint PDL1 molecule in a HIF-1α dependent manner, which hampers the functionality of infiltrated T cells [71, 72].”
RetractedTodoric, J., Umemura, A., Taniguchi, K., & Karin, M. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm027 · Cited by 46
Hypoxia and hypoxia-inducible factors in myeloid cell-driven host defense and tissue homeostasis
Jantsch, J., & Schödel, J. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.009 · Cited by 46
Hypoxia in bone metastasis and osteolysis
Todd, V. M., & Johnson, R. W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.004 · Cited by 55
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Najafi, A., Keykhaee, M., Khorramdelazad, H., Karimi, M. Y., Samimi, L. N., Aghamohamadi, N., Karimi, M., Falak, R., & Khoobi, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113483 · Cited by 50
Targeting intratumoral hypoxia to enhance anti-tumor immunity
Semenza, G. L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.002 · Cited by 53
Anti‐angiogenesis in colorectal cancer therapy
Yang, Z., Zhang, X., Bai, X., Xi, X., Liu, W., & Zhong, W. (2024) · Cancer Science · doi:10.1111/cas.16063 · Cited by 57
“156,157 Tumor hypoxia is primarily attuned by a transcription factor family, described as HIFs.”
BackgroundHuang, S., Chung, J. Y., Li, C., Wu, Y., Qiao, G., To, K., & Tang, P. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217272 · Cited by 49
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu, J., Fu, L., Wu, R., Che, L., Liu, G., Ran, Q., Xia, Z., Liang, X., & Zhao, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517959 · Cited by 74
Zhou, Y., Miao, J., Wu, H., Tang, H., Kuang, J., Zhou, X., Peng, Y., Hu, D., Shi, D., Deng, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17214 · Cited by 47
“A previous study [26] demonstrated that PD-L1 is a direct target of hypoxia-induced factor-1α (HIF1α) and PD-L1 expression was up-regulated under hypoxia.”
BackgroundMethodRoles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond
Khoshbin, A. P., Eskian, M., Keshavarz‐Fathi, M., & Rezaei, N. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0531-9 · Cited by 46
“MDSCs are among the stromal cells which express PD-L1 in the tumor microenvironment (Iwata et al. 2016; Noman et al. 2014; Zhang et al. 2017).”
BackgroundThe role of the immune system in brain metastasis.
Leibold, A. T., Monaco, G. N., & Dey, M. (2019) · PubMed · Cited by 54
Zhang, L., Yu, Z., Tu, Q., Xue, X., Zhu, X., & Zhao, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200128105459 · Cited by 56
Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer
Sureshbabu, S. K., Chaukar, D. A., & Chiplunkar, S. V. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13436 · Cited by 51
Hypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
Retooling Cancer Nanotherapeutics’ Entry into Tumors to Alleviate Tumoral Hypoxia
Sun, X. J., Ni, N., Ma, Y., Wang, Y., & Leong, D. T. (2020) · Small · doi:10.1002/smll.202003000 · Cited by 47
Yadollahi, P., Jeon, Y., Ng, W. L., & Choi, I. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.241 · Cited by 52
Group Young Researchers in Inflammatory Carcinogenesis, Wandmacher, A. M., Mehdorn, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13194932 · Cited by 58
Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance
Peng, J., Yin, X., Yun, W., Meng, X., & Huang, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216108 · Cited by 48
Qiu, C., Wang, W., Xu, S., Li, Y., Zhu, J., Zhang, Y., Lei, C., Li, W., Li, H., & Li, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12182-0 · Cited by 49
Chouaïb, S., Umansky, V., & Kiéda, C. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73874 · Cited by 51
“Recently, it has been demonstrated that HIF-1α (but not HIF-2α) could also strongly upregulate expression of the negative immune checkpoint molecule programmed death ligand (PD-L)-1 (also known as B7-H1 or CD274 on MDSC from tumor bearing mice [61].”
BackgroundRegulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins
Yang, Q., Cao, W., Wang, Z., Zhang, B., & Liu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.015 · Cited by 46
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy
Takacs, G. P., Flores‐Toro, J., & Harrison, J. K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107790 · Cited by 48
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript suppressive cell types include tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and T regulatory (Treg) cells.”
BackgroundInfluentialCisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
Wangpaichitr, M., Theodoropoulos, G., Nguyen, D. J. M., Wu, C., Spector, S. A., Feun, L. G., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147379 · Cited by 47
T lymphocyte cell: A pivotal player in lung cancer
Wu, Y., Yuan, M., Wang, C., Chen, Y., Zhang, Y., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102778 · Cited by 59
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114646 · Cited by 48
Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy
Li, W., Pan, X., Chen, L., Cui, H., Mo, S., Pan, Y., Shen, Y., Shi, M., Wu, J., Luo, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186383 · Cited by 59
“Hypoxia viaHIF-1a can induce the expression of PD-L1 on cancer cells and tumor-infiltrating MDSCs, leading to immune escape (120, 121).”
BackgroundThe Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies
Vijayanathan, Y., & Ho, I. A. W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020669 · Cited by 52
“MDSC exploits the lactate-induced stabilization of HIF α to suppress T cell activities [146], exacerbate hypoxic conditions [147], and perpetuate the acidification of the GBM TME, creating a persistent immunosuppressive environment [148].”
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy
Kamran, N., Chandran, M., Lowenstein, P. R., & Castro, M. G. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.008 · Cited by 52
Prado-García, H., Romero‐Garcia, S., Puerto-Aquino, A., & Rumbo‐Nava, U. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1979-x · Cited by 50
“11, Calu-1, MRC-5, and MCF-7 cells; the MCF-7 results were similar to others previously reported [16].”
ResultKumar, S., Davra, V., E. Obr, A., Geng, K., L. Wood, T., De Lorenzo, M. S., & Birge, R. B. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1376155 · Cited by 44
Deng, S., Clowers, M. J., Velasco, W. V., Ramos-Castaneda, M. A., & Moghaddam, S. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01556 · Cited by 45
“MDSCs also express the immune checkpoint molecule PD-L1, which binds to PD-1 on T cells resulting in T cell exhaustion (176).”
BackgroundLiu, W., Ren, D., Xiong, W., Jin, X., & Zhu, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02253-0 · Cited by 45
Funaki, S., Shintani, Y., Kawamura, T., Kanzaki, R., Minami, M., & Okumura, M. (2017) · Oncology Reports · doi:10.3892/or.2017.5894 · Cited by 43
Yero, A., Bouassa, R. M., Ancuța, P., Estaquier, J., & Jenabian, M.-A. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.01.001 · Cited by 47
Recent Advances in Perfluorocarbon-Based Delivery Systems for Cancer Theranostics
Yang, Y., Liu, Y., & Jiang, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00116 · Cited by 46
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
Ramapriyan, R., Vykunta, V. S., Vandecandelaere, G., Richardson, L. G., Sun, J. M., Curry, W. T., & Choi, B. D. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108667 · Cited by 49
T cell-based cancer immunotherapy: opportunities and challenges
Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 53
Endothelial cell dysfunction in viral hemorrhage and edema
Mackow, E. R., Gorbunova, E. E., & Gavrilovskaya, I. N. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00733 · Cited by 49
“Consistent with HPS responses in patients, both hypoxia and interferons induce the expression of PD-L1 (Schreiner et al., 2004; Muhlbauer et al., 2006; Noman et al., 2014).”
BackgroundAG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization
Bastian, A., Matsuzaki, S., Humphries, K. M., Pharaoh, G. A., Doshi, A., Zaware, N., Gangjee, A., & Ihnat, M. A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.040 · Cited by 42
Jayakumar, A., & Bothwell, A. L. M. (2017) · Neoplasia · doi:10.1016/j.neo.2017.04.006 · Cited by 46
“MDSCs suppress T cells by depleting essential arginine with IL-4–dependent arginase or by engaging PD-1 [15,20].”
BackgroundInfluentialMa, B., Wells, A. H., & Clark, A. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.021 · Cited by 49
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 46
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 55
Tumor microenvironment in glioblastoma: The central role of the hypoxic–necrotic core
Bayona, C., Ranđelović, T., & Ochoa, I. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218216 · Cited by 59
Foks, A. C., van Puijvelde, G. H. M., Wolbert, J., Kröner, M. J., Frodermann, V., van der Heijden, T., van Santbrink, P. J., Boon, L., Bot, I., & Kuiper, J. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw114 · Cited by 45
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.